Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
26 août 2021 08h00 HE
|
Excision BioTherapeutics
CRISPR-based therapies as a curative approach to HIV infection included in the program for first time.Collaboration with Temple University includes research on EBT-101, a CRISPR-based therapeutic...
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
29 juil. 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of...
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
27 mai 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
24 mai 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board
05 mai 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer
03 mai 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
01 avr. 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, April 01, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs
17 févr. 2021 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
30 nov. 2020 14h47 HE
|
Excision BioTherapeutics
San Francisco, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV –...
CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer
03 nov. 2020 09h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapeutics to cure viral infectious diseases, announced today the...